Relief Therapeutics Aktie [WKN DE: A1H80W / ISIN: CH0100191136]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Relief Therapeutics

18.09.24		Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 (EQS Group)
02.09.24		Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 (EQS Group)
30.08.24		Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update (EQS Group)
05.08.24		Relief Therapeutics Secures up to $11 Million from Royalty Sales (EQS Group)
27.06.24		RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting (EQS Group)
03.06.24		Relief Therapeutics Announces Executive Changes (EQS Group)
30.05.24		Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders (EQS Group)
08.05.24		Relief Therapeutics Announces New Executive Leadership Team strengthening capabilities to guide the Company through pipeline development initiatives (EQS Group)
30.04.24		Relief Therapeutics has published its Annual Report (EQS Group)
26.04.24		RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting (EQS Group)
27.03.24		RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting (EQS Group)
22.03.24		Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE (EQS Group)
28.02.24		Relief Therapeutics Renews CHF 50 million Share Subscription Facility (EQS Group)
05.12.23		Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth (EQS Group)
22.11.23		Relief Therapeutics Announces CEO Transition (EQS Group)
10.10.23		Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone (EQS Group)
15.09.23		Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update (EQS Group)
01.09.23		Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (EQS Group)
30.08.23		Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA (ACER-001) with Acer Therapeutics (EQS Group)
19.07.23		Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health (EQS Group)
23.06.23		Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East (EQS Group)
23.06.23		RELIEF THERAPEUTICS Holding SA Announces Closing of CHF 5 Million Private Placement (EQS Group)
20.06.23		RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders (EQS Group)
16.06.23		RELIEF THERAPEUTICS Holding SA Announces CHF 5 Million Private Placement (EQS Group)
26.05.23		RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders (EQS Group)
15.05.23		Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory (EQS Group)
12.05.23		Relief Therapeutics Has Filed its 2022 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (EQS Group)
03.05.23		Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares (EQS Group)
01.05.23		Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA Commercial Launch Progressing Ahead of Schedule (EQS Group)
28.04.23		Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders (EQS Group)
17.04.23		Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100 (EQS Group)
14.04.23		Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update (EQS Group)
05.04.23		Relief Therapeutics Announces Executive Leadership Team Change (EQS Group)
04.04.23		Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders (EQS Group)
03.04.23		Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board (EQS Group)
22.03.23		Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023 (EQS Group)
17.03.23		Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting (EQS Group)
16.03.23		Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe (EQS Group)
15.03.23		Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA (EQS Group)
28.02.23		Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars (EQS Group)
14.02.23		Relief Therapeutics Announces Enrollment of First Three Patients in Proof-of-Concept Clinical Trial of RLF-TD011 for the Treatment of Epidermolysis Bullosa (EQS Group)
08.02.23		Relief Therapeutics Provides an Update on its Financing Strategy (EQS Group)
17.01.23		Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom (EQS Group)
27.12.22		Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission (EQS Group)
27.12.22		Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA for Patients with Urea Cycle Disorders (EQS Group)
20.12.22		Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements (EQS Group)
14.12.22		Relief Therapeutics to Participate in January Investor Meetings (EQS Group)
13.12.22		Relief Therapeutics Announces Issuance of Shares from Authorized Capital (EQS Group)
08.12.22		Relief Therapeutics Announces Executive Leadership Team Changes (EQS Group)
21.11.22		APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival (EQS Group)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Bitcoin bald bei 100.000 Dollar? MicroStrategy-CEO zeigt sich bullish - 100k-Party schon geplant

Pierer Mobility-Aktie zweistellig im Plus: Pierer dementiert Mateschitz-Einstieg bei KTM

voestalpine-Aktie mit Verlusten: Stabile Erdgasversorgung trotz möglicher Unterbrechungen aus Russland

UN-Klimagipfel in Baku: Baerbock warnt vor 'Killerstürmen'

NEL ASA-Aktie fällt immer tiefer: Analysten sehen Risiken und raten zum Verkauf

Angespannte Stimmung in Frankfurt: LUS-DAX gibt am Nachmittag nach

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	24.11.2024 12:35
Kaufwert:	EUR
	Hinzufügen Speichern